sumIARY A highly specific inhibition enzyme linked immunosorbent assay (ELISA) using murine monoclonal antibodies to treponemes has been developed to diagnose syphilis. The monoclonal antibodies used in this study were reactive to antigens of both Treponema pallidum and Treponema pertenue and not to antigens of non-pathogenic treponemes. Inhibition of the binding ofmonoclonal antibody to the treponemal antigens was successful with serum antibodies of patients with syphilis in an inhibition ELISA using monoclonal antibodies raised against Tpallidum antigens with molecular weights of 42 and 47 kilodaltons. In contrast, the binding of monoclonal antibodies obtained by immunising mice with treponemal membrane protein TmpB, derived from recombinant DNA was not inhibited by serum antibodies from patients with syphilis. The sensitivity of the inhibition ELISA using monoclonal antibody against the 47 kilodalton T pallidum antigen was 93% in 58 serum samples from patients with untreated syphilis. The sensitivity was 79% if the monoclonal antibody against the 42 kilodalton Tpallidum antigen was used. By a combination ofthe test results obtained in these two inhibition assays a sensitivity of 97% in the 58 serum samples from untreated patients and 64% in 64 from treated patients was obtained. The specificity ofthe inhibition ELISA performed with either monoclonal antibody was 100% in 500 serum samples from non-infected people. The specificity in 432 non-infected patients attending a sexually transmitted disease clinic was 98.8% for the monoclonal antibody against the 42 kilodalton antigen, 99.5% for the monoclonal antibody against the 47 kilodalton antigen, and 98.4% for the combined antibodies. The sensitivity and specificity ofthe inhibition ELISA using the combination oftest results obtained by the application of the monoclonal antibodies against the 42 kilodalton treponemal membrane protein, TmpA, and against the 47 kilodalton Tpallidum antigen were comparable with those of the Treponema pallidum haemagglutination assay (TPHA) and the fluorescent treponemal antibody absorption (FTA-ABS) test for diagnosing early untreated disease. The inhibition ELISA offers the potential for additional confirmation of early untreated syphilis. Its use for confirming late untreated syphilis is still under investigation. The test is highly specific for pathogenic treponemes and does not need sorbens.
(T pallidum) as antigen. In these serological tests a sorbens is therefore often used to remove serum antibodies that are not specific for T pallidum.'-3 The effectiveness of such a sorbens is not well defined, which stresses the need for serological tests using well defined specific antigens. Immunoassays using purified antigens4 or recombinant proteins56 and immunoblotting techniques' have been proposed as serological tests for syphilis without the need for a sorbens.
The application ofmonoclonal antibodies (MoAbs) to detect treponemal antibody may provide a highly specific tool for diagnosing treponematoses. Such a 308 Development and evaluation ofa MoAb inhibition ELISA to diagnose syphilis test, which takes advantage of the high specificity of MoAbs, will probably show the high specificity required of a confirmatory test.
Studies of the reactivity of MoAbs raised against T pallidum or its components have resulted in MoAbs that were specific for pathogenic treponemes and those that were reactive with non-pathogenic and pathogenic spirochaetes.''4 Those studies also showed that the pathogen specific MoAbs could not yet distinguish between different pathogenic subspecies of treponemes, such as Tpallidum subsp pallidum, subsp pertenue, and subsp carateum. This agrees with the observation that T pallidum subsp pallidum (which causes syphilis) and subsp pertenue (which causes yaws) showed only minor differences in their protein patterns in two dimensional gels, western blots, and in studies of their genetic relation.'516 Binding of pathogen specific MoAbs to Tpallidum antigens can be inhibited by the serum of patients suffering from syphilis,'3 which indicates that a competitive inhibition assay using pathogen specific MoAbs may be suitable to diagnose syphilis. In this study eight monoclonal antibodies raised to three different Tpallidum antigens of molecular weights 47, 42, and 34 kilodalton were investigated for their suitability for use in an inhibition ELISA. We developed an inhibition ELISA using MoAbs directed to 42 and 47 kilodalton proteins and compared this assay for sensitivity and specificity with the Tpallidum haemagglutination assay (TPHA), fluorescent treponemal antibody absorption (FTA-ABS) test, and the Venereal Disease Research Laboratory (VDRL) test for diagnosing untreated and treated syphilis.
Patients, materials, and methods

ANTIGENS
Tpallidwn subsp pallidum, Tpallidum subsp pertenue (Tpertenue), and Tphagedenis, biotype Reiter, were used to evaluate the specificity of the different monoclonal antibodies used in this study. T pallidum (Nichols strain) was cultured by serial passage in rabbit testes. Treponemes were extracted from the rabbit testicular tissue and subsequently purified by being urografin density centrifuged, as described previously."'1' Preparations of 1010 treponemes/ml in phosphate buffered saline (PBS) were stored at -70°C. Tpertenue, strain Gauthier, kindly provided by P Hindersson, Copenhagen, was essentially prepared in the same way as Tpallidum. Tphagedenis was cultured in Brewer's thioglycollate medium with 10% (v/v) heat inactivated rabbit serum as described previously. '9 Before being used in ELISA or immunoblotting experiments, the treponemes were suspended in TRIS he MoAbs were purified by adding saturated ammonium sulphate solution to the ascites fluids to make a final saturation of 50%, which was mixed for one hour at 4°C by slow rotation. The insoluble proteins were pelleted by being centrifuged for 10 minutes at 10 000 x g. The pellet was rinsed with 50% saturated ammonium sulphate and centrifuged again. The final pellet was dissolved in 10 mmol/l sodium phosphate buffer (disodium hydrogen and sodium dihydrogen phosphate and 0.01 mmol/l calcium chloride, pH 6.8) 
SDS-PAGE AND WESTERN BLOTTING
Sonicated T pailidum, T pertenue, and T phagedenis were dissolved in 3% sodium dodecyl sulphate (SDS) by being heated in a boiling water bath for three minutes under reducing conditions using 2% 2-mercaptoethanol. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed using 13% slab gels (17 x 12 cm) as described by Laemmli.6 Immunoblotting was performed to identify the components of the pathogenic and nonpathogenic treponemes to which the monoclonal antibodies were directed. Electrophoretic transfer of proteins to nitrocellulose was performed with a transblot apparatus (Biorad, USA) using the method of Bumette.2' After the proteins had been transferred, the nitrocellulose was cut into separate strips. Each strip was soaked in PBS containing 0.05% Tween 20 (polysorbate 20) (PBS-T) for 15 minutes and incubated for one hour with MoAb diluted 1:100 in PBS-T. After being rinsed in PBS-T for 10 minutes, the nitrocellulose strips were incubated for one hour with 1:1000 dilution of antibodies to mouse (RIVM, The Netherlands) or human (Nordic, The Netherlands) immunoglobulin labelled with horseradish peroxidase. The nitrocellulose strips were rinsed again, the substrate solution, which contained 0-6 mg/ml tetramethyl-benzidine, 2 mg/ml dioctylsodiumsulphosuccinate and 0Q015% (v/v) hydrogen peroxide in citrate/ phosphate buffer (5 mmol/ml citric acid, 10 mmol/1 disodium hydrogen phosphate, pH 5.0, and 25% (v/v) IJsselmuiden, Top, Stolz, van Eijk ethanol), was added, and they were incubated for 10 minutes.
TITRATION OF MONOCLONAL ANTIBODIES IN Tpailidum ELISA
The optimum dilution of each monoclonal antibody labelled with horseradish peroxidase was assessed by titration in the Tpallidum ELISA. For this purpose a microtitration plate precoated with T pallidum ultrasonicate was incubated for one hour with labelled MoAb in increasing dilutions. Ten minutes after adding 0'1 ml substrate solution (0. 1 mg/ml tetramethylbenzidine, 0-009% hydrogen peroxide, and 0-1 1 mol/l sodium acetate, adjusted with citric acid to pH 5.5), the reaction was stopped by adding 3 mol/l sulphuric acid. The extinctions were measured and plotted against the appropriate dilution ofthe labelled monoclonal antibody.
INHIBITION ELISA
Preliminary experiments had shown that maximum inhibition of monoclonal antibody binding to the antigens by serum antibodies was achieved by incubating a low dilution of the patient's serum before incubating the MoAb. The patient's serum diluted to the same extent had also to be added to the MoAb solution during its incubation. To incorporate these conditions, the inhibition ELISA was performed as follows: 0 1 ml of T pallidum sonicate (2.7 x 107 treponemes/ml PBS) was coated on to the wells of a microtitration plate (96 wells, Dynatech, Germany) by incubating the plates for one hour at 37°C. The plate was rinsed for 30 seconds in a continuous low pressure flow of rinsing buffer (TS-buffer containing 0.05% Tween 20) . The patient's serum diluted 1:5, 1:50, and 1:100 in PBS-T was then added to the wells and incubated for one hour at 37°C. The plates were rinsed with PBS-T and appropriately diluted test serum mixed with labelled MoAbs at the indicated working dilution was added to the wells and incubated for one hour at 37°C. The plates were rinsed with PBS-T, and 0.1 ml substrate solution was added to the wells and incubated. The reaction was stopped by adding 50 ul of3 mol/1 sulphuric acid. The extinction was measured with a multiscan (Titertek) at 450 nm.
Appropriate control samples were included in each assay. The reactivity of each MoAb was checked by incubating without serum the appropriate MoAb labelled with horseradish peroxidase. The specificity of the reaction was checked using alpha-fetoprotein labelled with horseradish peroxidase as a control on each plate.
Results
SPECIFICITY OF MONOCLONAL ANTIBODIES
To define the reactivity and specificity of MoAbs The reactivity of the MoAbs to T pallidum, T pertenue, and Tphagedenis was analysed by immunoblotting. Figure 1 shows Table 2 shows the results of testing 58 serum samples from patients with early syphilis and 500 from noninfected people in the inhibition ELISA, TPHA, and FTA-ABS test to assess the sensitivity and specificity of the inhibition ELISA. All 58 samples from patients with untreated early syphilis reacted in at least the FTA-ABS test. More samples from patients with secondary and latent syphilis reacted in the inhibition ELISA using labelled MoAb C3E5 than when MoAb 1-14M1 was used which resulted in sensitivities of 98% (mean 100% for secondary syphilis and 96% for latent syphilis) with C3E5 and 77% (mean 83% for secondary syphilis and 72% for latent syphilis) with 1-14M1. For primary syphilis, the inhibition ELISA Of the 64 samples from treated patients, 39 (61%) reacted in the inhibition ELISA using MoAb C3E5, and 24 (38%) when MoAb 1-14M1 was used; 41 (64%) reacted positively when the results using both MoAbs were combined. The sensitivity of the inhibition ELISA for diagnosing treated syphilis after combining the test results of the two MoAbs (64%) was less than the sensitivities of the TPHA (92%) and the FTA-ABS (86%) test.
Discussion
In the present study an inhibition ELISA for the serodiagnosis ofsyphilis using antitreponemal MoAbs is reported. Eight MoAbs were investigated for their suitability in the inhibition ELISA. Three MoAbs had been raised against Tpallidum organisms and five were raised against the 34 kilodalton recombinant protein, TmpB. All eight MoAbs were reactive in the T pailidum ELISA, which indicated that the Tpallidum antigens used in the inhibition ELISA contained the epitopes to which the MoAbs were reactive. Furthermore, the MoAbs reacted in the TPHA and the FTA test with the exception of MoAb 1-14M1 in the FTA test. Although MoAb 1-14M1 was raised against the 42 kilodalton protein TmpA, which is associated with treponemal membrane,a4 it did not react with presumed exposed treponemal surface antigens in the FTA test. As MoAbs directed to the 34 kilodalton TmpB were not inhibited by serum from patients with syphilis, they were not suitable for use in the inhibition ELISA. Homologous inhibition of labelled MoAb by its unlabelled counterpart was shown for all MoAbs except MoAb D6F7C6, which indicated that the labelling of D6F7C6 may have altered the structure of its antigen binding sites.
Regarding its specificity in people assumed to be healthy, the inhibition ELISA using MoAbs C3E5 and 314 1-14M1 was comparable with the specificities of the TPHA and the FTA-ABS test. In the 432 serum samples from patients attending the STD clinic, the specificity of the inhibition ELISA was lower. This may have been because incomplete disease histories were obtained from these patients, who were at high risk for acquiring STDs.
In patients with untreated syphilis the sensitivities of the inhibition ELISA were 79% using MoAb 1-14M 1, 93% using C3E5, and 97% using both. The sensitivity of the inhibition ELISA using both MoAbs was therefore comparable with those of the TPHA and the FTA-ABS test. The use of MoAb C3E5 alone provided a test with 93% sensitivity. This, in combination with the test results obtained with MoAb 1-14M1, slightly enhanced the sensitivity for patients with primary syphilis, but should be confirmed by testing more serum samples.
The ideal inhibition assay takes advantage of a MoAb that is able to react at all stages ofsyphilis. Such a MoAb was not found in this study. Several possible explanations exist for the differences in reactivity between the MoAbs in the inhibition ELISA. The avidity of the MoAb may be higher than that of the polyclonal serum directed to the common determinant, which results in less inhibition. Serum antibodies reactive to the common determinant may be present in small amounts. Serum antibodies directed to the appropriate determinant may not be present, depending on the stage of syphilis.
The epitope to which the MoAb was reactive may possibly not be presented to the host immune system during natural infection. This possibility may apply to the MoAbs raised against the recombinant protein TmpB. The use of these MoAbs in the inhibition ELISA indicated that they could not be inhibited by serum from patients with syphilis. This could have been due to an antibody response of mice to epitopes of the recombinant treponemal protein, TmpB, that differed from the epitopes of the naturally occurring TmpB from treponemes. In a direct ELISA using TmpB as antigen, reactions were seen in only a limited number of serum samples from patients with untreated syphilis that gave positive results in other tests for syphilis, which indicated that certain patients do not produce antibodies to the 34 kilodalton protein TmpB (Schouls et al, submitted for publication). This confirms the poor antibody response to TmpB in man.
The use of more than one MoAb in the inhibition ELISA may overcome the disadvantages of using a single MoAb. As can be expected from this theoretical viewpoint, however, the specificity of the test would decline for each additional MoAb that is used. This was shown by combining the results of the inhibition ELISA using MoAbs C3E5 and 1-14M1 to screen a high risk population. In 64 serum samples from IJsselmuiden, Top, Stolz, van Eijk patients with treated syphilis that were not reactive in the VDRL but were reactive in at least one treponemal test, the sensitivity of the inhibition ELISA using MoAb 1-14M1 was appreciably less than the sensitivity using MoAb C3E5.
The fact that MoAb 1-14M1 was less effective in diagnosing treated syphilis than MoAb C3E5 agrees with the observation that the serum antibodies reactive to the 42 kilodalton TmpA derived from recombinant DNA showed a rapid decline in reactivity soon after the patients were treated.28
Technically, non-reactive serum samples showed high variation of extinction in the inhibition ELISA. This was circumvented by testing each serum sample at three different dilutions. The dilutions that were chosen were based on the limited number of samples tested. An improvement in future experiments may be the inclusion of dilutions higher than 1:100 of each serum specimen.
The application of MoAbs in an inhibition assay offers the opportunity to show antibody response to distinct epitopes. Although there is a considerable similarity between the antigenic structures of pathogenic treponemes, epitopes of different pathogenic treponemal species may differ. In future, monoclonal antibodies directed to such epitopes may provide an inhibition ELISA to differentiate between various pathogenic treponemes.
In conclusion, the inhibition ELISA using the combination of test results of two MoAbs directed to 42 and 47 kilodalton treponemal proteins may be a highly specific and sensitive test for diagnosing early untreated syphilis. Because of its high specificity, the inhibition ELISA may have potential for confirming early untreated syphilis. Furthermore, the inhibition ELISA forms a model for the study of a wider panel of monoclonal antibodies whose inhibition pattern may possibly give guidance to the stage of syphilis and treatment status.
